Detection of Prion Protein in Urine-Derived Injectable Fertility Products by a Targeted Proteomic Approach by Van Dorsselaer, Alain et al.
Detection of Prion Protein in Urine-Derived Injectable
Fertility Products by a Targeted Proteomic Approach
Alain Van Dorsselaer
1*, Christine Carapito
1, Franc ¸ois Delalande
1, Christine Schaeffer-Reiss
1, Daniele
Thierse
1,H e ´le `ne Diemer
1, Douglas S. McNair
2, Daniel Krewski
3, Neil R. Cashman
4*
1Laboratoire de Spectrome ´trie de Masse Bio-Organique, Universite ´ de Strasbourg, IPHC, CNRS, UMR7178, Strasbourg, France, 2Cerner Corporation, Kansas City, Missouri,
United States of America, 3McLaughlin Centre for Population Health Risk Assessment, University of Ottawa, Ontario, Canada, 4Brain Research Centre, Department of
Medicine (Neurology), University of British Columbia, Vancouver, British Columbia, Canada
Abstract
Background: Iatrogenic transmission of human prion disease can occur through medical or surgical procedures, including
injection of hormones such as gonadotropins extracted from cadaver pituitaries. Annually, more than 300,000 women in the
United States and Canada are prescribed urine-derived gonadotropins for infertility. Although menopausal urine donors are
screened for symptomatic neurological disease, incubation of Creutzfeldt-Jakob disease (CJD) is impossible to exclude by
non-invasive testing. Risk of carrier status of variant CJD (vCJD), a disease associated with decades-long peripheral
incubation, is estimated to be on the order of 100 per million population in the United Kingdom. Studies showing infectious
prions in the urine of experimental animals with and without renal disease suggest that prions could be present in
asymptomatic urine donors. Several human fertility products are derived from donated urine; recently prion protein has
been detected in preparations of human menopausal gonadotropin (hMG).
Methodology/Principal Findings: Using a classical proteomic approach, 33 and 34 non-gonadotropin proteins were
identified in urinary human chorionic gonadotropin (u-hCG) and highly-purified urinary human menopausal gonadotropin
(hMG-HP) products, respectively. Prion protein was identified as a major contaminant in u-hCG preparations for the first
time. An advanced prion protein targeted proteomic approach was subsequently used to conduct a survey of gonadotropin
products; this approach detected human prion protein peptides in urine-derived injectable fertility products containing
hCG, hMG and hMG-HP, but not in recombinant products.
Conclusions/Significance: The presence of protease-sensitive prion protein in urinary-derived injectable fertility products
containing hCG, hMG, and hMG-HP suggests that prions may co-purify in these products. Intramuscular injection is a
relatively efficient route of transmission of human prion disease, and young women exposed to prions can be expected to
survive an incubation period associated with a minimal inoculum. The risks of urine-derived fertility products could now
outweigh their benefits, particularly considering the availability of recombinant products.
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Introduction
Transmissible spongiform encephalopathies (TSEs), or prion
diseases, such as scrapie, bovine spongiform encephalopathy
(BSE) and Creutzfeldt-Jakob disease (CJD), are sub-acute
neurodegenerative disorders in which the infectious agent is an
aggregated, misfolded host prion protein that propagates through
‘template directed misfolding’. The disease-associated protein
isoform, generically designated PrP
TSE, is derived from a normal,
non-infectious, host-derived cellular isoform termed PrP
C.T h e
most common human TSE, CJD, occurs in forms which are
sporadic (sCJD), iatrogenic (iCJD) or genetic (e.g. familial CJD:
fCJD). The emergence of a new variant CJD (vCJD) in the UK
and France, almost certainly the result of human consumption of
BSE-contaminated bovine tissues, has affected 216 individuals in
11 countries worldwide as of March 2010 [1]. Although the
primary zoonotic epidemic of vCJD is probably in decline, a
survey of lymphoreticular tissues in the UK estimated that 237
people per million population (95% confidence interval: 49–692
per million) were ‘silent carriers’ of vCJD [2]. These results
suggest that many countries may have asymptomatic citizens
’incubating’ the disease for decades. Thus, it is possible that
secondary outbreaks may occur through iatrogenic transmission
via organ transplantation, contaminated surgical instruments,
and human-derived therapeutic products; indeed, four cases of
blood-borne transmission of the vCJD prion agent have already
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' o sbeen documented in the UK. Iatrogenic transmission of classical
CJD has also been demonstrated through dural and corneal
transplantation and neurosurgical instruments. Notably, in the
1990s 194 individuals were infected through intramuscular
injections of pituitary growth hormone derived from human
cadavers [3]. The latter episode not only demonstrated the high
infectivity of parenterally injected CJD prions (recipient disease
rates exceeded 10% in some French batches), but also raised the
possibility that chromatography systems used to purify therapeu-
tic hormones and peptides may enrich human prions. Four cases
of iatrogenic transmission of CJD through fertility treatment
involving human pituitary-derived gonadotropin have also been
reported in Australia [4].
It is now clear that infectious prions are excreted into the urine
in renal disease states. Studies from the Aguzzi laboratory in
2005 convincingly demonstrated the presence of fully infectious
prion particles in the urine of scrapie mice with co-existing renal
inflammation [5]. Although PrP
TSE levels were below the limits
of detection by immunoblotting in this study, intracerebral
inoculation of concentrated urine transmitted scrapie in host
mice. More recent work has demonstrated that renal pathology
is not required for urinary prion excretion in experimental
animals. In 2006, the Gabizon group [6] first demonstrated
prionuria in the absence of renalinflammation byinducing prion
disease in naı ¨ve hamstersthroughinoculationof scrapie urine.In
2007, Gregori and colleagues [7] and Murayama and colleagues
[8] demonstrated detectable levels of PrP
TSE in the urine of
s c r a p i eh a m s t e r sf o rt h ef i r s tt i m e .U r i n a r yP r P
TSE was only
detectable at the symptomatic stage of the disease. However,
these findings do not imply that urine is ‘safe’ if PrP
TSE is
undetectable; Aguzzi and colleagues failed to detect PrP
TSE in
urine subsequently proven to be infectious [5]. Furthermore, the
studies of both Aguzzi [5] and Gabizon [6] found infectivity in
the urine during the presymptomatic incubation period before
the appearance of clinical disease. Gonzalez-Romero and
colleagues recently confirmed the presence of templating-
competent PrP
TSE in the urine of experimentally infected
animals using protein misfolding cyclic amplification [9]. Using
a rigorous quantitative method, Gregori and colleagues [7] have
recently reported that the titer of prions in urine of scrapie-
infected hamsters was several units of infectivity per mL, similar
to that observed in hamster blood.
Collectively, these studies suggest that the urine of prion-infected
individuals may be infectious before the appearance of clinical signs
– even before PrP
TSE is detectable in the urine. These and other
studies [10,11] also indicate that, while renal disease may facilitate
prionuria, such pathology is not a prerequisite for urinary prion
transmission. Recently, Kuwabara and colleagues [12] have
identified prion protein in urine-derived gonadotropins. Although
this class of products is not administered to patients for extended
periods, the number of injections and the amount of total protein
administered could expose patients to a potential risk of prion
transmission. Using advanced proteomics methods, we now report
the detection of prion protein in commercially available urine-
derived gonadotropins, but not in recombinant fertility products.
Results
Identification of non-gonadotropin proteins in human
chorionic gonadotropin (hCG) preparations using
electrophoresis and mass spectrometry (MS)
After 2D gel electrophoresis of hCG products (Figure 1),
protein spots found to be present in the molecular weight range
of approximately 14–70 kDa in u-hCG and recombinant-hCG
(r-hCG) were analyzed by electrospray ionization MS (ESI–
MS/MS), and identified using internationally available
databases.
Figure 1. 2D gel electrophoresis separation of urinary and recombinant hCG products (6,500 IU loaded). (A) u-hCG manufacturer A. (B)
u-hCG Manufacturer B. (C) r-hCG Manufacturer D. (D) Zoom views on the regions of gels (A) and (B) with spots containing PrP peptides encircled.
doi:10.1371/journal.pone.0017815.g001
Prion Protein in Urine-Derived Fertility Products
PLoS ONE | www.plosone.org 2 March 2011 | Volume 6 | Issue 3 | e17815Several non-gonadotropin proteins were identified in the u-
hCG derived preparations (Table 1) but not in the r-hCG
preparation. For u-hCG-manufacturer A, prion protein was
identified as one of the major non-gonadotropin proteins present.
Within urinary impurities, major prion protein (Swissprot
accession number P04156) was identified in several 2D gels as a
series of spots in the mass range 21–25 kDa for u-hCG-
manufacturer A and at about 29 kDa for u-hCG-manufacturer
B. The isoelectric point (pI) ranged from four to five for both
samples. The fact that major prion protein was identified in several
spots is probably due to heterogeneous glycosylation and degraded
prion protein forms [13]. In contrast, no prion protein was
identified in the r-hCG preparation.
Considering the importance of these findings, liquid chroma-
tography tandem MS (LC-MS/MS) was conducted to confirm the
presence of prion protein in both u-hCG products. The tryptic
peptides identified by LC-MS/MS in u-hCG preparations are
reported in Figure 2. A total of five peptides were identified from
the mature human prion protein sequence covering amino acids
121–228 which is in agreement with recently published charac-
terization of the truncated prion protein forms in human urine
[14]. MS/MS spectra of all the peptides identified are provided in
Figure S1.
Separation of gonadotropin and non-gonadotropin
proteins in human menopausal gonadotropin (hMG)
using electrophoresis
Two samples of hMG and one of a combination of recombinant
human follicle-stimulating hormone and recombinant human
luteinizing hormone (r-hFSH/r-hLH) were analyzed by 2D gel
Table 1. Non-gonadotropin protein profile identified in u-hCG products.
N Identified human proteins
Accession
number
u-hCG
manufacturer A
u-hCG
manufacturer B
1 Major prion protein P04156 X X
2 Apolipoprotein D P05090 X X
3 Beta-2-glycoprotein 1 P02749 X X
4 Complement decay-accelerating factor P08174 X X
5 Alpha-1-microglobulin (protein AMBP) P02760 X X
6 CD59 glycoprotein P13987 X X
7 Uromodulin P07911 X X
8 Growth/differentiation factor 15 Q99988 X X
9 Endosialin Q9HCU0 X X
10 Protein delta homolog 1 P80370 X X
11 Fibrillin-1 P35555 X X
12 Matrix metalloproteinase-9 P14780 X X
13 Plasminogen P00747 X
14 Complement factor B P00751 X
15 Tumor necrosis factor receptor superfamily member 1B P20333 X
16 Hepatocyte growth factor activator Q04756 X
17 EGF-containing fibulin-like extracellular matrix protein 1 Q12805 X
18 Tumor necrosis factor receptor superfamily member 1A P19438 X
19 Connective tissue growth factor O18739 X
20 Basement membrane-specific heparan sulfate proteoglycan core protein P98160 X
21 Plasma serine protease inhibitor (protein C inhibitor) P05154 X
22 Insulin-like growth factor-binding protein 7 Q16270 X
23 Zinc-alpha-2-glycoprotein P25311 X
24 Folate receptor alpha P15328 X
25 Kininogen-1 P01042 X
26 Protein S100-A7 (Psoriasin) P31151 X
27 Pro-epidermal growth factor P01133 X
28 Fibulin-2 P98095 X
29 Collagen alpha-1(III) chain P02461 X
30 Apolipoprotein(a) P08519 X
31 Probable carboxypeptidase PM20D1 Q6GTS8 X
32 Complement factor H-related protein 1 Q03591 X
33 Cystatin-M Q15828 X
u-hCG = urinary human chorionic gonadotropin.
doi:10.1371/journal.pone.0017815.t001
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impurities known to be present in hMG (manufacturer A), a lower
amount (600 IU FSH) of this sample was loaded. Since no
information was available on the purity of hMG (manufacturer C),
it was handled as hMG-HP preparation by loading a total of 1,125
IU FSH. Comparative analysis indicated that both hMGs tested
were less pure than hMG-HP and contained high levels of total
proteins, mainly urinary impurities.
Identification of non-gonadotropin proteins in hMG-HP
preparations using electrophoresis and MS
After 2D gel electrophoresis of two batches of hMG-HP
(Figures 4A and 4B), protein spots were analyzed by LC-MS/MS,
and identified using internationally available databases.
In total, 34 non-gonadotropin proteins were identified in the
protein profile of the hMG-HP preparations (Table 2). No
impurities were identified in the r-hFSH/r-hLH preparation
Figure 2. Human prion protein (PrP) sequence (mature form in bold).
*Tryptic peptides identified in human chorionic gonadotropin (hCG)
preparations (PrP 121-136, PrP 137-148, PrP 157-164, PrP 209-220, and PrP 221-228) are underlined.
doi:10.1371/journal.pone.0017815.g002
Figure 3. 2D gel electrophoresis separation of urinary hMG and recombinant hFSH/hLH products. (A) hMG Manufacturer A (600 IU
loaded). (B) hMG Manufacturer C (1,125 IU loaded). (C) r-hFSH/r-hLH Manufacturer D (1,125 IU loaded).
doi:10.1371/journal.pone.0017815.g003
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impurities identified in hMG-HP products by manufacturer A
increased the number of non-gonadotropin proteins identified by
the scientific community to 39.
Targeted prion protein quantification in gonadotropin
preparations using liquid chromatography selected
reaction monitoring (LC-SRM)
LC-SRM analysis was performed directly on all hCG samples to
allow specific detection of tryptic peptides from the prion protein,
confirming unambiguously the 2D gel data from urine-derived
hCG samples. The same technique was used to test the other
products included in this study (u-hCG, hMG and hMG-HP), and
was able to detect and quantify the human prion protein (Table 3).
It should be noted that primary experiments were performed
using only one vial of each product. Among the urinary
preparations, hMG-HP showed the presence of prion protein
but the level was not quantifiable (data not shown). The
experiment was then repeated with 6 pooled vials and prion
presence was confirmed. No trace of prion protein was detected
when the same process (using a larger number of vials) was carried
out for the recombinant preparation r-hLH (Table 3).
The tryptic prion peptides PrP (209–220) and PrP (221–228)
were used for SRM detection and peptide PrP (209–220) for
quantification. As the human PrP peptide sequence (221–228) is
identical to the related bovine PrP peptide, it was used to
simultaneously evaluate the presence of human and bovine prion
sequence. These tryptic prion peptides are located in the human
prion carboxy-terminal sequence, and thus allow the detection of
several potential truncated prion protein forms (see Figure 2)
[13,16]. LC-SRM is therefore suitable to evaluate the potential
presence of bovine prion peptides in recombinant products, if
bovine prion protein is present at levels higher than the limit of
detection (LOD). The LOD was experimentally established and
found to be product-dependent. According to the results reported
in Table 3, no human or bovine prion peptides were detected in r-
hCG, r-hLH, and r-hFSH/r-hLH products from manufacturer D.
Discussion
Using classical proteomic analyses, prion protein was detected
for the first time in two u-hCG preparations, and was among 33
different non-gonadotropin proteins identified as contaminants of
these pharmaceutical products. In contrast, r-hCG preparations
were negative for prion proteins.
In one of the two u-hCG products tested, human prion protein
was among the ten major contaminants. The fact that prion
protein sequences were identified in several spots on our 2D
electrophoresis gels is likely due to the presence of heterogeneous
glycosylation and degraded prion protein forms. It is also worth
noting that in the u-hCG preparation of manufacturer A,
plasminogen was identified among the urinary impurities;
plasminogen has been identified as a binding protein for disease-
associated prion protein [17].
Both hMG and hMG-HP were tested using 2D gel electropho-
resis. The results confirmed that the two hMGs tested were less
pure than hMG-HP and contained a large number of total
proteins (mainly represented by urinary impurities). Non-gonad-
otropin proteins present in hMG-HP products were identified by
MS, resulting in 34 co-purified contaminants. Only gonadotropin
proteins were seen in all the recombinant preparations analyzed
by 2D gel electrophoresis. Using this 2D-gel/LC-MS/MS
proteomic workflow, prion proteins were identified only in u-
hCG and not in hMG-HP preparations. In parallel, a targeted
proteomic approach (LC-SRM) was developed to detect human
prion proteins which are sensitive to proteases. The method was
optimized to provide quantitative data in each container of
Figure 4. 2D gel electrophoresis separation of highly purified urinary hMG and recombinant hFSH/hLH products (1,125 IU loaded).
(A) hMG-HP Manufacturer A-Product 1. (B) hMG-HP Manufacturer A-Product 2. (C) r-hFSH/r-hLH Manufacturer D.
doi:10.1371/journal.pone.0017815.g004
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technique currently available with a limit of detection in the low
femtomolar range. This approach for prion protein detection,
identification and quantification was used on all gonadotropin
pharmaceutical preparations included in our study, including both
urinary (hCG, hMG, hMG-HP) and recombinant products.
All urine-derived preparations tested, produced by different
manufacturers, showed the presence of human prion proteins in
varying amounts. These findings demonstrate that the purification
processes for different urine-derived preparations are unable to
remove prion proteins from the source material and that the
process controls employed do not permit the identification of this
contaminant.
Do the prion protein peptides detected in this study originate
from infectious prions? Preparation of tryptic peptides is preceded
by solubilization in 8M urea, which is adequate to disaggregate
and denature the disease-associated isoform of the prion protein
rendering it susceptible to trypsin digestion. It is also clear that
native and diseased isoforms of the prion protein share affinity for
chromatography substrates utilized to purify peptide hormones
[3]. Finally, infectious prions can range down in size to oligomers
of a few dozen prion protein molecules [18], which would be
undetectable by existing biochemical methodologies including MS
methods employed in this study.
Although no cases of human prion disease due to the use of
urinary gonadotropins have been recognized to date, the
epidemiological signal for transmission may be difficult to detect.
Each year, more than 300,000 young women in the US and
Canada are prescribed urine-derived gonadotropins for infertility.
Although the Food and Drug Administration and Health Canada
Table 2. Non-gonadotropin protein profile identified in hMG-HP products.
N Identified impurities
Accession
number
hMG-HP manufacturer
A Product 1
hMG-HP manufacturer A
Product 2
1 Plasma serine protease inhibitor (protein C inhibitor) P05154 XX XX
2 Apolipoprotein D P05090 XX XX
3 Insulin-like growth factor-binding protein 7 Q16270 XX XX
4 Leukocyte elastase inhibitor P30740 XX XX
5 Alpha-2-antiplasmin P08697 XX X
6 Zinc-alpha-2-glycoprotein P25311 X XX
7 Serum albumin P02768 X X
8 Folate receptor alpha P15328 X X
9 Urokinase plasminogen activator surface receptor Q03405 X X
10 Afamin P43652 X X
11 Kininogen-1 P01042 X X
12 Reversion-inducing cysteine-rich protein with Kazal motifs O95980 X X
13 Alpha-1-antitrypsin P01009 X X
14 Plasminogen P00747 X X
15 Beta-2-glycoprotein 1 P02749 X X
16 Thrombospondin type-1 domain-containing protein 4 Q6ZMP0 X X
17 Protein S100-A7 (Psoriasin) P31151 X X
18 Alpha-1-acid glycoprotein 1 P02763 X X
19 Complement decay-accelerating factor P08174 X X
20 Sialate O-acetylesterase Q9HAT2 X
21 Alpha-1-microglobulin (protein AMBP) P02760 X
22 Ig kappa chain C region P01834 X
23 Ig gamma chain C region P01857 X
24 Peptidoglycan recognition protein O75594 X
25 Golgi phosphoprotein 2 Q8NBJ4 X
26 Delta-like protein 1 O00548 X
27 Death-associated protein kinase 1 P53355 X
28 CD27 antigen P26842 X
29 Serotransferrin P02787 X
30 TNF receptor superfamily member 21 O75509 X
31 CD59 glycoprotein P13987 X
32 Folate receptor gamma P41439 X
33 Platelet endothelial aggregation receptor 1 Q5VY43 X
34 TNF receptor superfamily member 4 P43489 X
hMG-HP = highly purified urinary human menopausal gonadotropin.
doi:10.1371/journal.pone.0017815.t002
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for prion disease transmission, the discovery of full infectivity in the
urine of nephritic scrapie-infected mice in 2005 led to new
requirements for product labeling and a review of donor
procedures and manufacturing processes. Additional recent
findings suggest that urinary prion excretion can occur without
renal pathology [6,7]. These results warrant a reassessment as to
whether the risks of urine-derived fertility products could now
outweigh their benefits, particularly considering the availability of
recombinant products that do not require human urine as a
substrate.
Although urinary gonadotropins have been previously charac-
terized as safe [19,20], this opinion may be overly optimistic in
view of the present findings, supported by results from other
recently published studies. Notably, blood products were once also
considered ‘safe’, based on the lack of detectable prions in vCJD
using an inadequately sensitive mouse bioassay [21]. In line with
recent published studies, the 2010 updated World Health
Organization tables on ‘Tissue infectivity distribution in transmissible
spongiform encephalopathy’ moved urine from the category of ‘Tissues
with no detectable infectivity’ to the category of ‘Lower-infectivity tissue’
(the latter category includes blood) [22].
Current urine collection systems pool the urine of thousands of
donors and, unlike the blood collection system, do not allow for
donor tracing. There is also no mechanism of ensuring that the
designated donor is actually the one who provides the urine, as
donation is normally done at home. However, even if donor
management and tracing were flawless, the fact that prionuria may
exist well before the onset of clinically overt prion disease, without
being detectable by current methods, remains a cause for concern.
Furthermore, the now indisputable detection of prions in urine of
experimental animals, the lack of a species barrier for human-to-
human transmission, the relative efficiency of the intramuscular
injection route for prion transmission, and the young age of
fertility drug recipients all support application of the ‘precaution-
ary principle’ for urinary derived pharmaceuticals. As risk
management paradigms shift towards more proactive approaches
intended to ‘anticipate and prevent’ emerging risks [23–26], a
careful examination of the risk of transmission of human prion
disease through the use of urine-derived hormones and peptides
would appear to be warranted.
Materials and Methods
Source of material
Commercial products of urinary human chorionic gonadotro-
pin (u-hCG) from Ferring (Switzerland) and Organon (Denmark),
human menopausal gonadotropin derived from urine (hMG) from
Ferring (Switzerland) and Livzon (China); and hMG highly
purified (hMG-HP) from Ferring (Switzerland) were used
(Table 4). In addition, recombinant human chorionic gonadotro-
pin (r-hCG), serum-free recombinant human follitropin alfa in
association with lutropin alfa (r-hFSH + r-hLH) and human
Table 3. Results of prion protein peptides analysis in gonadotropin preparations by LC-SRM.
Commercial
product Manufacturer Concentration
Prion detection
(peptide 209-220,
peptide 221-228) Prion quantification (peptide 209-220)
Prion content
(pmoles/vial) CV (%)
Limit of detection
(pmoles/vial)
u-hCG A 5,000 IU Yes 116.21 5 2.88
B – product 1 5,000 IU Yes 30.38 7 2.00
B – product 2 5,000 IU Yes 15.78 6 0.62
hMG A 75 IU Yes 6.78 6 1.35
C 75 IU Yes 5.38 12 0.96
hMG-HP A – product 1* 75 IU Yes 0.21 10 0.01
A – product 2* 75 IU Yes 0.10 13 0.01
r-hCG D 250 mgN o ,LOD - 0.47
r-hFSH/r-hLH D 150 IU/75 IU No ,LOD - 0.09
r-hLH D* 75 IU No ,LOD - 0.04
For all products a single vial was used for measurements. For products with *, six vials were pooled in order to minimize protein material losses.
LC-SRM = liquid chromatography selected reaction monitoring; CV = coefficient of variation; u-hCG = urinary human chorionic gonadotropin; hMG = urinary human
menopausal gonadotropin; hMG-HP = highly purified hMG; r-hCG = recombinant hCG; r-hFSH = recombinant human follicle-stimulating hormone; r-hLH =
recombinant human luteinizing hormone.
doi:10.1371/journal.pone.0017815.t003
Table 4. Characteristics of commercial products analyzed.
Commercial
product Manufacturer Strength
Country
producer
u-hCG A 5000 IU Switzerland
B – product 1 5000 IU Denmark
B – product 2 5000 IU Denmark
hMG A 75 IU Switzerland
C 75 IU China
hMG-HP A – product 1 75 IU Switzerland
A – product 2 75 IU Switzerland
r-hCG D 250 mg Switzerland
r-hFSH/r-hLH D 150IU/75IU Switzerland
r-hLH D 75 IU Switzerland
u-hCG = urinary human chorionic gonadotropin; hMG = urinary human
menopausal gonadotropin; hMG-HP = highly purified hMG; r-hCG =
recombinant hCG; r-hFSH = recombinant human follicle-stimulating hormone;
r-hLH = recombinant human luteinizing hormone.
doi:10.1371/journal.pone.0017815.t004
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(Switzerland) (Table 4).
Identification of non-gonadotropin proteins using
electrophoresis and MS
a) Sample preparation. A total amount of 6,500 IU of hCG
samples, 600 IU of hMG sample A and 1,125 IU of hMG sample
C, 1,125 IU of hMG-HP samples and 1,125 IU r-hFSH/r-hLH
sample were pretreated by ultrafiltration to remove non-protein
product excipients such as lactose or mannitol which are
incompatible with the first dimension of 2D SDS-PAGE
(VIVASPIN-2 filter, Sartorius VS0291; cut off: 3,000 Da,
centrifugation at 4,000 g, temperature was constantly
maintained at 4uC). The volume of solution was reduced to
about 0.6 mL of pure water.
b) SDS-PAGE. Samples were loaded onto a 2D SDS–PAGE
gel. Proteins were separated on a first dimension according to their
pI at 86,000 VH, and then on a second dimension according to
their molecular weight. Following 2D separation, the gels were
stained by silver or Coomassie blue staining. Detected proteins
were removed from the gel using a gel cutter (PROTEINEERsp,
Bruker Daltonics, Bremen, Germany), washed, reduced, alkylated
and dehydrated automatically with a MassPrep robot (Waters,
Milford, MA). The gel pieces were digested with porcine trypsin
(Promega, Madison, WI, USA). The resulting tryptic peptides
were extracted with 60% acetonitrile in 0.5% formic acid and
analyzed by nanoflow liquid chromatography tandem mass
spectrometry (nanoLC-MS/MS).
c) Protein identification by NanoLC-MS/MS
analysis. NanoLC-MS/MS analysis was performed using an
Agilent 1100 series nanoLC-Chip system (Agilent Technologies,
Palo Alto, USA) coupled to an HCT Plus ion trap (Bruker
Daltonics, Bremen, Germany). The chip was composed of a
Zorbax 300SB-C18 analytical column (43 mm 675 mm, with a
5 mm particle size) and a Zorbax 300SB-C18 enrichment column
(40 nL, 5 mm). Elution of the peptides was performed at a flow rate
of 300 nL.minute
21 with a 8–40% linear gradient (solvent B,
98%ACN/0.1%FA) over 7 minutes.
The voltage applied to the capillary cap was optimized to
21,750 V and the mass range was 250–2,500 m/z. For tandem
MS experiments, the system was operated in data-dependent
acquisition mode with automatic switching between MS and MS/
MS. The three most abundant precursor ions were selected to be
further isolated and fragmented. The MS/MS scanning was
performed in the ultrascan resolution mode at a scan rate of
26.000 m/z per second. A total of six scans were averaged to
obtain an MS/MS spectrum.
Mass data collected during nanoLC- MS/MS analysis were
processed, converted into *.mgf files and were interpreted using a
local Mascot server (Matrix Science, London, UK). Searches were
performed against the SwissProt database (57.4 version, 470,369
entries) using a target/decoy approach and without molecular
weight or isoelectric point restrictions. The tolerance on mass
measurements was set to 0.20 Da for both MS and MS/MS
modes. One tryptic missed cleavage per peptide was allowed and
some variable modifications were taken into account such as
carbamidomethylation for cysteine and oxidation for methionine.
Validation criteria were applied in order to retain no decoy hit.
Targeted prion protein quantification in gonadotropin
preparations using LC-SRM
a) Sample preparation. After removal of the non-protein
product excipients as described for the 2D gel electrophoresis, the
total protein content was determined by Bradford assay using the
Bio-Rad Protein Assay Kit (Bio-Rad Laboratories, Hercules, CA,
USA) according to the manufacturer’s instructions for the
Microplate Protocol, with a working range of 1–25 mg. Bovine
serum albumin was used as standard. Samples were evaporated to
dryness and rediluted with 200 mL of 8 M urea, 0.1 M
NH4HCO3. Reduction was performed with addition of 3.5 mlo f
700 mM DTT, 37uC, 30 minutes (final concentration 12 mM)
and alkylation with addition of 12 ml of 700 mM IAA, 25uC, dark,
1 hour (final concentration 40 mM). In order to perform the
tryptic digestion, this solution was diluted with 1,500 mL of 0.1 M
fresh NH4HCO3. Digestion was carried out by adding 1 mgo f
bovine trypsin (Promega) per 100 mg of proteins and maintained at
37uC overnight. Desalting and further concentration was carried
out by adsorption using C18 Sep-Pak cartridges (Sep-Pak Vac 1cc
50 mg, tC18, Waters) and peptides were eluted with 600 mLo f
50%ACN/0.1%FA. After evaporation to dryness, the peptide
fraction was re-dissolved in water to a final concentration of 1 mg/
mL.
b) LC-SRM quantification of human PrP. The approach
developed was mainly based on the AQUA strategy previously
described by Gerber et al. for the absolute quantitative analysis of
proteins [27].
Stable isotope labeled internal standard peptides (Sigma Aldrich,
St. Louis, MO) were introduced in protein samples just before
proteolytic digestion. Both the isotope labeled AQUA peptide and
the unlabeled native peptide (produced during proteolytic cleavage
of the target protein) were then measured by LC-SRM. Similar to
small molecule isotope dilution strategies, the isotope-labeled
standard and the analyte are identical except for their masses. In
ananalogousfashiontoclassicisotopedilutionapproaches,the mass
difference allows the mass spectrometer to differentiate between the
twonearlyidenticalspecies.Sincetheamountofinternal standardis
known, and the ratio between amounts of internal standard and
analyte can be determined from the mass spectra, the amount of the
analyte peptide can be calculated.
The quantification was performed directly on vials or pooled
vials. Peptides already detected and identified in 2D gel spots by
the classical LC-MS/MS proteomic approach were targeted by
LC-SRM allowing a specific detection of the four peptide
sequences of the human PrP: 137–148, 157–164, 209–220, and
221–228. A fifth peptide, corresponding to peptide 209–220 with
the methionine oxidized, was also targeted. Three different
amounts of standard peptides were spiked in (250, 750, and
2,250 femtomoles) in order to make sure that the final
quantification was performed in the linear range. All analyses
were performed in triplicate to evaluate the coefficient of variance.
Results were given in picomoles per vial.
Because of the low amounts of standard peptides spiked in the
samples, special care had to be taken to prepare these standard
solutions. To minimize expected losses of peptides by irreversible
adsorption on the walls of the tubes at very low concentrations,
dilution ofthestocksolutionwasmadeinlow-binding500 mLtubes.
The dilutions from these stock solutions were made extemporane-
ously, briefly mixed and spiked in samples within less than 2 min
after dilution. We have verified that at the final diluted
concentrations, there is no signal intensity loss when 1 mLi s
analyzed in less than 3 min. The followingdilutionprocess has been
used: 1 nanomole of lyophilized AQUA peptides was dissolved in
20 ml of 10%FA, sonicated for 3 min and then 180 ml of 0.1%FA
was added and vortexed to obtain a stock solution at 5 pmol/ml.
c) Micro LC separation. Separation was made on an
Agilent 1100 HPLC system equipped with a C18 column
(Zorbax 300 SB C18 Agilent, 15060.3 mm, 3.5 mm) using a
water/acetonitrile gradient at 4 mL.minute
21 (2–22% acetonitrile
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Agilent, 1761 mm, 3.5 mm, reverse mode).
d )S R Mm e t h o ds e t u p .A triple quadrupole mass
spectrometer (QQQ G 6410, Agilent Technologies) was used.
The best transitions per peptide were optimized using the
Peptide Optimizer software tool. One fully tryptic peptide (209–
220) was used for quantification. Peptide (221–228) gave in all
samples in which PrP was detected a lower amount than peptide
(209–220) indicating that the PrP must undergo C-terminal
cleavages. Hence, the quantification using the more internal
peptide (209–220) was more relevant. The other two peptides
(137–148 and 157–164) were excluded for quantification as they
correspond to proline cleavages and displayed incomplete and
irreproducible trypsin cleavages. The list of the optimized
transitions is given in Table 5 for the native peptides and the
internal isotope labeled standard peptides. Dynamic SRM
method setup was used with a dwell time of 200 ms per
transition. The most intense fragment was used as a quantifier
and the two other as qualifiers; the tolerances for the fragments’
ratios are listed in Table 5.
Supporting Information
Figure S1 MS/MS spectra of peptides identified in the
2-D gel electrophoresis spots as PrP tryptic peptides.
(PDF)
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Table 5. Optimized transitions for prion protein native peptides and isotope labeled standard peptides.
Peptides
Precursor ion m/z
(charge state)
Quantifier (A) m/z
(charge state,
fragment type)
Qualifier 1 (B) m/z
(charge state,
fragment type)
Qualifier 2 (C) m/z
(charge state,
fragment type) B/A C/A
Native 209-220 778,4 (2+) 696,4 (1+, y5) 1228,6 (1+, y9) 1100,5 (1+, y8) 0,35+/225% 1+/225%
AQUA 209-220 783,4 (2+) 706,4 (1+, y5) 1238,6 (1+, y9) 1110,6 (1+, y8) 0,35+/225% 1+/225%
Native 221-228 522,7 (2+) 629,3 (1+, y4) 466,3 (1+, y3) 700,3 (1+, y5) 1+/230% 1+/230%
AQUA 221-228 527,8 (2+) 639,4 (1+, y4) 476,3 (1+, y3) 710,4 (1+, y5) 1+/230% 1+/230%
SRM was used to follow peptide fragments, the most intense fragment was used as a quantifier (A) and the two secondary fragments were used as qualifiers (B and C).
doi:10.1371/journal.pone.0017815.t005
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